Validation of the French version of the McLean screening instrument for borderline personality disorder (MSI-BPD) in an adolescent sample.
Adolescent
Borderline personality disorder
MSI-BPD
Screening
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
12 05 2020
12 05 2020
Historique:
received:
24
02
2020
accepted:
30
04
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
22
12
2020
Statut:
epublish
Résumé
The study examines the psychometric properties of the French version of the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) created by M. Zanarini to screen borderline personality disorder in clinical and non-clinical populations. In this multicentric longitudinal study from the European Network on Borderline Personality Disorder, a sample of 84 adolescent patients from five psychiatric centres and 85 matched controls without psychiatric comorbidity completed the MSI-BPD, French version, and were interviewed with the Structured Interview for DSM-IV Personality (SIDP-IV), in order to assess the presence or absence of borderline personality disorder. The MSI-BPD showed excellent internal consistency (α = 0.87 [0.84;0.90]). Compared to the semi-structured reference interview (SIDP-IV), the MSI-BPD showed substantial congruent validity (AUC = 0.93, CI 95%: 0.90-0.97). The optimal cut-off point in the present study was 5 or more, as it had relatively high sensitivity (0.87) and specificity (0.85). In our sample, the cut-off point (7 or more) proposed by the original developers of the MSI-BPD showed high specificity (0.95) but low sensitivity (0.63). The French version of the MSI-BPD is now available, and its psychometric properties are satisfactory. The French version of the MSI-PBD can be used as a screening tool for borderline personality disorder, for clinical purposes or in research studies.
Sections du résumé
BACKGROUND
The study examines the psychometric properties of the French version of the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) created by M. Zanarini to screen borderline personality disorder in clinical and non-clinical populations.
METHOD
In this multicentric longitudinal study from the European Network on Borderline Personality Disorder, a sample of 84 adolescent patients from five psychiatric centres and 85 matched controls without psychiatric comorbidity completed the MSI-BPD, French version, and were interviewed with the Structured Interview for DSM-IV Personality (SIDP-IV), in order to assess the presence or absence of borderline personality disorder.
RESULTS
The MSI-BPD showed excellent internal consistency (α = 0.87 [0.84;0.90]). Compared to the semi-structured reference interview (SIDP-IV), the MSI-BPD showed substantial congruent validity (AUC = 0.93, CI 95%: 0.90-0.97). The optimal cut-off point in the present study was 5 or more, as it had relatively high sensitivity (0.87) and specificity (0.85). In our sample, the cut-off point (7 or more) proposed by the original developers of the MSI-BPD showed high specificity (0.95) but low sensitivity (0.63).
CONCLUSIONS
The French version of the MSI-BPD is now available, and its psychometric properties are satisfactory. The French version of the MSI-PBD can be used as a screening tool for borderline personality disorder, for clinical purposes or in research studies.
Identifiants
pubmed: 32398037
doi: 10.1186/s12888-020-02643-8
pii: 10.1186/s12888-020-02643-8
pmc: PMC7216676
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
222Subventions
Organisme : Pfizer Foundation (Fr)
ID : 000
Pays : International
Références
Can J Psychiatry. 2012 Apr;57(4):230-7
pubmed: 22480588
J Can Acad Child Adolesc Psychiatry. 2018 Aug;27(3):155-156
pubmed: 30038651
Rev Psiquiatr Salud Ment. 2016 Oct - Dec;9(4):195-202
pubmed: 27067102
Psychol Assess. 2005 Sep;17(3):278-87
pubmed: 16262454
Psychother Psychosom Med Psychol. 2010 Sep-Oct;60(9-10):391-6
pubmed: 20225166
J Pers Disord. 2003 Dec;17(6):568-73
pubmed: 14744082
Pediatrics. 2014 Oct;134(4):782-93
pubmed: 25246626
Lancet. 2011 Jan 1;377(9759):74-84
pubmed: 21195251
Nord J Psychiatry. 2009 Nov;63(6):475-9
pubmed: 19548177
J Pers Disord. 2019 Dec 30;:1-11
pubmed: 31887102
J Nerv Ment Dis. 2015 Jan;203(1):3-7
pubmed: 25536097
J Pers Disord. 2015 Feb;29(1):71-8
pubmed: 24932872
Assessment. 2014 Apr;21(2):210-7
pubmed: 23344914
J Behav Health Serv Res. 2016 Apr;43(2):272-80
pubmed: 24875431
Arch Gen Psychiatry. 2001 Jun;58(6):590-6
pubmed: 11386989
J Pers Disord. 2008 Aug;22(4):353-64
pubmed: 18684049